Oncologie

, Volume 14, Issue 2, pp 96–102 | Cite as

Les effets secondaires de l’hormonothérapie et leur gestion

  • C. Hennequin
  • P. Mongiat-Artus
  • L. Quero
  • D. Pouessel
  • S. Culine
Mise au Point Update
  • 85 Downloads

Résumé

Les effets secondaires de la déprivation androgénique sont de mieux en mieux connus. À côté des bouffées de chaleur et de la dysfonction érectile, les complications cardiovasculaires et osseuses doivent être prises en compte à la fois dans les indications des médicaments mais aussi dans la surveillance du traitement. L’induction d’un diabète peut être un événement précoce, survenant dans les six mois après le début du traitement. Les dyslipidémies sont plus rares. L’augmentation de la fréquence des accidents cardiovasculaires ou de la mortalité cardiaque reste discutée. Il est maintenant bien démontré que la déprivation androgénique augmente de manière modérée le risque d’événements osseux de type ostéoporotique. Cette meilleure connaissance des effets secondaires nécessite la réalisation d’un bilan clinique et paraclinique initial et lors de la surveillance d’une hormonothérapie prolongée.

Mots clés

Cancer de prostate Hormonothérapie Syndrome métabolique Ostéoporose 

Side effects of androgen deprivation and their management

Abstract

The knowledge of secondary effects of androgen deprivation has improved. Besides hot flushes and erectile dysfunction, cardiovascular and bone complications must be taken into consideration once medication has been indicated and also during treatment. The onset of diabetes can occur early, within six months after the start of treatment, with dyslipidaemia being far rarer. An increase in the frequency of cardiovascular events and cardiac mortality remains controversial. There is now sufficient evidence to show that androgen deprivation moderately increases the risk of osteoporotic-type bone disorders. A greater understanding of the secondary effects will require an initial clinical and paraclinical study, as well as the monitoring of longterm hormone therapy.

Keywords

Prostate cancer Androgen deprivation Metabolic syndrom Osteoporosis 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Références

  1. 1.
    Alibhai SM, Duong-Hua M, Sutradhar R, et al. (2009) Impact of androgen deprivation therapy on cardiovascular disease and diabetes. J Clin Oncol 27: 3452–3458PubMedCrossRefGoogle Scholar
  2. 2.
    Antonarakis ES, Blackford AL, Garrett-Mayer E, et al (2007) Survival in men with nonmetastatic prostate cancer treated with hormone therapy: a quantitative systematic review. J Clin Oncol 25: 4998–5008PubMedCrossRefGoogle Scholar
  3. 3.
    Basaria S, Muller DC, Carducci MA, et al. (2006) Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation therapy. Cancer 106: 581–588PubMedCrossRefGoogle Scholar
  4. 4.
    Batsis JA, Nieto-Martinez RE, Lopez-Jimenez F (2007) Metabolic syndrome: from global epidemiology to individualized medicine. Clin Pharmacol Ther 82: 509–524PubMedCrossRefGoogle Scholar
  5. 5.
    Bolla M, Van Tienhoven G, Warde P, et al. (2010) External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. Lancet Oncol 11: 1066–1073PubMedCrossRefGoogle Scholar
  6. 6.
    Braga-Basaria M, Dobs AS, Muller DC, et al (2006) Metabolic syndrome in men with prostate cancer undergoing longterm androgen-deprivation therapy. J Clin Oncol 24: 3979–3983PubMedCrossRefGoogle Scholar
  7. 7.
    D’Amico AV, Chen MH, Renshaw AA, et al. (2008) Androgen suppression and radiation versus radiation alone for prostate cancer: a randomized trial. JAMA 299: 289–295PubMedCrossRefGoogle Scholar
  8. 8.
    D’Amico AV, Denham JW, Crook J, et al (2007) Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J Clin Oncol 25: 2420–2425PubMedCrossRefGoogle Scholar
  9. 9.
    DiBlasio CJ, Malcolm JB, Derweesh IH, et al. (2008) Patterns of sexual and erectile dysfunction and response to treatment in patients receiving androgen deprivation therapy for prostate cancer. BJU Int 102: 39–43PubMedCrossRefGoogle Scholar
  10. 10.
    Dickman PW, Adolfsson J, Astrom K, et al (2004) Hip fractures in men with prostate cancer treated with orchiectomy. J Urol 172: 2208–2212PubMedCrossRefGoogle Scholar
  11. 11.
    Efstathiou JA, Bae K, Shipley WU, et al. (2008) Cardiovascular mortality and duration of androgen deprivation for locally advanced prostate cancer: analysis of RTOG 92-02. Eur Urol 54: 816–823PubMedCrossRefGoogle Scholar
  12. 12.
    Efstathiou JA, Bae K, Shipley WU, et al (2009) Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG 85-31. J Clin Oncol 27: 92–99PubMedCrossRefGoogle Scholar
  13. 13.
    Gralow JR, Biermann JS, Farooki A, et al. (2009) NCCN Task Force Report: Bone Health in Cancer Care. J Natl Compr Canc Netw 7(Suppl 3): S1–S32; quiz S33–S5PubMedGoogle Scholar
  14. 14.
    Greenspan SL, Nelson JB, Trump DL, et al (2007) Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: a randomized trial. Ann Intern Med 146: 416–424PubMedGoogle Scholar
  15. 15.
    Higano CS (2008) Androgendeprivation-therapy-induced fractures in men with nonmetastatic prostate cancer: what do we really know? Nat Clin Pract Urol 5: 24–34PubMedCrossRefGoogle Scholar
  16. 16.
    Irani J, Salomon L, Oba R, et al (2010) Efficacy of venlafaxine, medroxyprogesterone acetate, and cyproterone acetate for the treatment of vasomotor hot flushes in men taking gonadotropin-releasing hormone analogues for prostate cancer: a double-blind, randomised trial. Lancet Oncol 11: 147–154PubMedCrossRefGoogle Scholar
  17. 17.
    Jiang HX, Majumdar SR, Dick DA, et al. (2005) Development and initial validation of a risk score for predicting in-hospital and 1-year mortality in patients with hip fractures. J Bone Miner Res 20: 494–500PubMedCrossRefGoogle Scholar
  18. 18.
    Keating NL, O’Malley AJ, Smith MR (2006) Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 24: 4448–4456PubMedCrossRefGoogle Scholar
  19. 19.
    Laaksonen DE, Niskanen L, Punnonen K, et al. (2004) Testosterone and sex hormone-binding globulin predict the metabolic syndrome and diabetes in middleaged men. Diabetes Care 27: 1036–1041PubMedCrossRefGoogle Scholar
  20. 20.
    Lage MJ, Barber BL, Markus RA (2007) Association between androgendeprivation therapy and incidence of diabetes among males with prostate cancer. Urology 70: 1104–1108PubMedCrossRefGoogle Scholar
  21. 21.
    Lakka HM, Laaksonen DE, Lakka TA, et al. (2002) The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 288: 2709–2716PubMedCrossRefGoogle Scholar
  22. 22.
    Lee H, McGovern K, Finkelstein JS, et al (2005) Changes in bone mineral density and body composition during initial and long-term gonadotropin-releasing hormone agonist treatment for prostate carcinoma. Cancer 104: 1633–1637PubMedCrossRefGoogle Scholar
  23. 23.
    Lu-Yao G, Stukel TA, Yao SL (2004) Changing patterns in competing causes of death in men with prostate cancer: a population based study. J Urol 171: 2285–2290PubMedCrossRefGoogle Scholar
  24. 24.
    Lu-Yao GL, Albertsen PC, Moore DF, et al (2008) Survival following primary androgen deprivation therapy among men with localized prostate cancer. JAMA 300: 173–181PubMedCrossRefGoogle Scholar
  25. 25.
    Mohler J, Bahnson RR, Boston B, et al. (2010) NCCN clinical practice guidelines in oncology: prostate cancer. J Natl Compr Canc Netw 8: 162–200PubMedGoogle Scholar
  26. 26.
    Morote J, Morin JP, Orsola A, et al (2007) Prevalence of osteoporosis during longterm androgen deprivation therapy in patients with prostate cancer. Urology 69: 500–504PubMedCrossRefGoogle Scholar
  27. 27.
    Muller M, Grobbee DE, den Tonkelaar I, et al. (2005) Endogenous sex hormones and metabolic syndrome in aging men. J Clin Endocrinol Metab 90: 2618–2623PubMedCrossRefGoogle Scholar
  28. 28.
    Nanda A, Chen MH, Braccioforte MH, et al (2009) Hormonal therapy use for prostate cancer and mortality in men with coronary artery disease-induced congestive heart failure or myocardial infarction. JAMA 302: 866–873PubMedCrossRefGoogle Scholar
  29. 29.
    Naoe M, Ogawa Y, Shichijo T, et al. (2006) Pilot evaluation of selective serotonin reuptake inhibitor antidepressants in hot flash patients under androgendeprivation therapy for prostate cancer. Prostate Cancer Prostatic Dis 9: 275–278PubMedCrossRefGoogle Scholar
  30. 30.
    Oefelein M, Ricchiuti V, Conrad M, et al (2002) Skeletal fractures negatively correlates with overall survival in men with prostate cancer. J Urol 168: 1005–1007PubMedCrossRefGoogle Scholar
  31. 31.
    Potosky AL, Knopf K, Clegg LX, et al. (2001) Quality-of-life outcomes after primary androgen deprivation therapy: results from the Prostate Cancer Outcomes Study. J Clin Oncol 19: 3750–3757PubMedGoogle Scholar
  32. 32.
    Punnen S, Cooperberg MR, Sadetsky N, et al (2011) Androgen deprivation therapy and cardiovascular risk. J Clin Oncol 29: 3510–3516PubMedCrossRefGoogle Scholar
  33. 33.
    Roach M 3rd, Bae K, Speight J, et al. (2008) Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610. J Clin Oncol 26: 585–591PubMedCrossRefGoogle Scholar
  34. 34.
    Ryan CW, Huo D, Demers LM, et al (2006) Zoledronic acid initiated during the first year of androgen deprivation therapy increases bone mineral density in patients with prostate cancer. J Urol 176: 972–978; discussion 978PubMedCrossRefGoogle Scholar
  35. 35.
    Saad F, Adachi JD, Brown JP, et al. (2008) Cancer treatment-induced bone loss in breast and prostate cancer. J Clin Oncol 26: 5465–5476PubMedCrossRefGoogle Scholar
  36. 36.
    Sadetsky N, Greene K, Cooperberg MR, et al (2011) Impact of androgen deprivation on physical well-being in patients with prostate cancer: Analysis from the CAPSURE (Cancer of the Prostate Strategic Urologic Research Endeavor) registry. Cancer 117: 4406–4413PubMedCrossRefGoogle Scholar
  37. 37.
    Saigal CS, Gore JL, Krupski TL, et al. (2007) Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer. Cancer 110: 1493–1500PubMedCrossRefGoogle Scholar
  38. 38.
    Sanda MG, Dunn RL, Michalski J, et al (2008) Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med 358: 1250–1261PubMedCrossRefGoogle Scholar
  39. 39.
    Shahinian V, Kuo Y, Freeman J, et al. (2005) Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 352: 154–164PubMedCrossRefGoogle Scholar
  40. 40.
    Sharifi N, Gulley JL, Dahut WL (2005) Androgen deprivation therapy for prostate cancer. JAMA 294: 238–244PubMedCrossRefGoogle Scholar
  41. 41.
    Smith MR, Eastham J, Gleason DM, et al. (2003) Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol 169: 2008–2012PubMedCrossRefGoogle Scholar
  42. 42.
    Smith MR, Egerdie B, Hernandez Toriz N, et al (2009) Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med 361: 745–755PubMedCrossRefGoogle Scholar
  43. 43.
    Smith MR, Fallon MA, Lee H, et al. (2004) Raloxifene to prevent gonadotropinreleasing hormone agonist-induced bone loss in men with prostate cancer: a randomized controlled trial. J Clin Endocrinol Metab 89: 3841–3846PubMedCrossRefGoogle Scholar
  44. 44.
    Smith MR, Lee WC, Brandman J, et al (2005) Gonadotropin-releasing hormone agonists and fracture risk: a claimsbased cohort study of men with nonmetastatic prostate cancer. J Clin Oncol 23: 7897–7903PubMedCrossRefGoogle Scholar
  45. 45.
    Smith MR, Malkowicz SB, Chu F, et al. (2008) Toremifene increases bone mineral density in men receiving androgen deprivation therapy for prostate cancer: interim analysis of a multicenter phase 3 clinical study. J Urol 179: 152–155PubMedCrossRefGoogle Scholar
  46. 46.
    Smith MR, McGovern FJ, Fallon MA, et al (2001) Low bone mineral density in hormone-naive men with prostate carcinoma. Cancer 91: 2238–2245PubMedCrossRefGoogle Scholar
  47. 47.
    Stone P, Hardy J, Huddart R, et al. (2000) Fatigue in patients with prostate cancer receiving hormone therapy. Eur J Cancer 36: 1134–1141PubMedCrossRefGoogle Scholar
  48. 48.
    Strum SB, McDermed JE, Scholz MC, et al (1997) Anaemia associated with androgen deprivation in patients with prostate cancer receiving combined hormone blockade. Br J Urol 79: 933–941PubMedCrossRefGoogle Scholar
  49. 49.
    Taylor LG, Canfield SE, Du XL (2009) Review of major adverse effects of androgen-deprivation therapy in men with prostate cancer. Cancer 115: 2388–2399PubMedCrossRefGoogle Scholar
  50. 50.
    Tsai HK, D’Amico AV, Sadetsky N, et al (2007) Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. J Natl Cancer Inst 99: 1516–1524PubMedCrossRefGoogle Scholar
  51. 51.
    VanderWalde A, Hurria A (2011) Aging and osteoporosis in breast and prostate cancer. CA Cancer J Clin 61: 139–156PubMedCrossRefGoogle Scholar
  52. 52.
    Wilke DR, Krahn M, Tomlinson G, et al (2010) Sex or survival: short-term versus long-term androgen deprivation in patients with locally advanced prostate cancer treated with radiotherapy. Cancer 116: 1909–1917PubMedCrossRefGoogle Scholar

Copyright information

© Springer Verlag France 2012

Authors and Affiliations

  • C. Hennequin
    • 1
    • 2
  • P. Mongiat-Artus
    • 2
  • L. Quero
    • 2
  • D. Pouessel
    • 2
  • S. Culine
    • 2
  1. 1.Service de cancérologie-radiothérapiehôpital Saint-LouisParisFrance
  2. 2.Groupe d’onco-urologiehôpital Saint-Louis, ParisParisFrance

Personalised recommendations